Nancy Kaiser

Nancy Kaiser (d.15 June 2008), is called patient 00 in the Ampligen trials. She was the first to be given Ampligen for the treatment of ME/CFS patient. Treatment was spearheaded and supervised by Dr. Daniel Peterson in 1988. As she was a severe patient, many treatments were tried prior, including IV acyclovir and gammaglobulin yet she continued to deteriorate. After a she improved for the first two years on the drug and, then, her improvements plateaued. After several more years, her health began to deteriorate again. She opted to stop Ampligen has it was no longer helping her.

Conflicting reports tell her experience with Ampligen. By her own words she told of the benefit of Ampligen at first. Later she soured to the drug and its manufacturing company, [Hemispherx Biopharma]], and discouraged patients from using it, going so far as to offer her phone number to potential trial subjects.

Nancy's journey with Ampligen is featured in Osler's Web, by Hillary Johnson:"'Nancy Kaiser had been on Ampligen for eight months. Her IQ continued to recover; it was currently 136, having been 88 when therapy began and 118 after three months of infusions. Kaiser's seizures had ended completely, and her eyesight - she had been plagued by transient blindness - had returned to normal. A multitude of other clinical and laboratory signs revealed improvement, too. On the strength of Kaiser's remarkable progress, HEM Pharmaceuticals had given Peterson permission to give the drug to ten more people.''"